|
Patent landscape, scope, and claims: |
United States Patent 9,439,911 (Sprayable Non-Occlusive Steroid Topical): Claim Scope, Patent Estate, and Generic Entry Risk
US Patent 9,439,911 claims a sprayable topical composition that is substantially non-occlusive and formulated as an emulsion with a non-polymeric emulsifier comprising sorbitan stearate, at least one topical steroid, a water phase, and a water-immiscible substance, with optional polymer, penetration enhancer, and functional/ingredient exclusions (notably substantially propellant-free and substantially propylene-glycol-free). Independent claim 1 is broad across many corticosteroids; dependent claims narrow to specific drug-moieties and ingredient classes, with additional process-feel attributes (droplets, non-foaming) and rheology.
What is US 9,439,911 and what does it cover in US claim language?
Core invention (independent claim 1):
A sprayable topical pharmaceutical composition with these required elements:
- At least one steroid (broad functional genus)
- Non-polymeric emulsifying agent comprising sorbitan stearate
- Water
- Water-immiscible substance
- Form must be “substantially non-occlusive to the skin.”
Independent claim 15 mirrors claim 1 but is more specific by requiring:
- A betamethasone compound (species genus)
- Non-polymeric emulsifier comprising sorbitan stearate
- Water
- Water-immiscible substance
- Substantially non-occlusive to the skin.
Functional constraints that narrow infringement:
- The composition must be substantially non-occlusive on skin (claims are formulation-performance driven).
- It must be sprayable (delivery format limitation that can be critical in claim construction and design-around).
Where the claims get specific (key dependent claim triggers)
Key claim features that become “switch points” for design-around:
-
Steroid identity (claim 2)
Includes: alclometasone dipropionate, beclomethasone dipropionate, betamethasone dipropionate, betamethasone valerate, fluocinolone acetonide, halobetasol propionate, hydrocortisone aceponate/acetate/valerate/butyrate, mometasone furoate, triamcinolone acetonide, clocortolone pivalate, clobetasol propionate, desoximetasone, fluticasone propionate.
-
Polymer optionality and specific polymer families (claims 3–5, 18–19, 10, 23)
Polymer is optional in claim 1, but once selected it is limited to cellulose/gums/alginate/phthalates with long lists of exemplified materials (e.g., ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropylcellulose, HPMC/HPC variants, xanthan gum, guar gum, alginates, and cellulose phthalates).
-
Penetration enhancer optionality and broad class with a numeric range (claims 7–9, 21–22)
Penetration enhancer:
- present at about 0.001% to about 15% by weight
- selected from polyol and esters/ethers/sulfoxides/fatty acids/fatty acid esters (and combinations).
-
Droplet formation and foam control (claims 11–12, 25–26)
- forms droplets upon application
- substantially non-foaming
-
Exclusions (claims 13–14, 27–28)
- substantially free of a propellant
- substantially free of propylene glycol
-
Viscosity range (claim 24)
~10 to ~15,000 centipoise (a numerical formulation limitation).
-
Betamethasone-specific concentration and salt esters (claims 16–17)
Betamethasone compound amounts equivalent to ~0.025% to ~0.1% betamethasone base, covering betamethasone benzoate, dipropionate, sodium phosphate, valerate.
-
Method of treatment (claims 29–30)
Uses are for treating a defined set of inflammatory dermatoses, including:
- atopic dermatitis, seborrhoeic dermatitis, eczema
- plaque psoriasis, erythroderma psoriasis
- psoriasis of the scalp
- steroid responsive dermatoses
- erythema, contact sensitivity reactions, and related disorders.
Which claim elements most constrain scope for infringement?
(1) “Substantially non-occlusive to the skin”
This is the principal performance limitation. In practice, it raises two infringement proof issues:
- The accused formulation must achieve non-occlusive behavior on skin under relevant conditions.
- The claim is not limited to an in vitro test method in the text provided, so the non-occlusivity characteristic can be litigated via expert-defined skin hydration/occlusion proxies, depending on the record of prosecution and any doctrine-of-equivalents framing.
From a freedom-to-operate standpoint, this is the hardest-to-design-around element if competitors are already operating in the same occlusion-reducing formulation space (e.g., avoiding occlusive petrolatum-like films).
(2) “Sprayable topical pharmaceutical composition”
This ties the formulation to a delivery characteristic. Two design-around levers typically used in topical spray systems:
- Change the delivery form so it is not “sprayable” as claimed (e.g., lotion, gel, foam, pump-applied stream).
- Keep topical formulation but use a different dispensing mechanism and argue it does not meet the claim’s “sprayable” limitation.
(3) “Non-polymeric emulsifying agent comprising sorbitan stearate”
This is a composition-anchoring requirement. It is not limited to sorbitan stearate alone: the claim requires an emulsifier that comprises sorbitan stearate and is non-polymeric.
Design-around levers:
- Replace sorbitan stearate with a different emulsifier system and move away from sorbitan stearate-containing emulsions.
- Use polymeric emulsifiers only is not compliant with the “non-polymeric emulsifying agent” requirement if sorbitan stearate is absent.
(4) Water-immiscible substance genus
Claim 1 and 15 require a water-immiscible substance from a broad list including oils (vegetable, mineral, saturated paraffin), fatty acids/esters, triglycerides, waxes, and hydrogenated oils. This element is hard to escape because the list is broad.
What formulations are protected by US 9,439,911?
A practical mapping from claim text to a competitor formulation checklist:
Claim 1 protected formulation class (steroid-agnostic within enumerated steroid list)
Protected if the product has:
- Sprayable topical emulsion-like composition
- Steroid (at least one of the claim 2 list, or potentially other steroid if claim 2 is not limiting in your asserted scope)
- Sorbitan stearate in a non-polymeric emulsifier
- Aqueous phase (water)
- Water-immiscible phase (broad oil/fatty/wax list)
- Meets substantially non-occlusive performance requirement
With optional limitations that may matter depending on asserted claim:
- Polymer present: cellulose/gum/alginate/phthalate types (specific enumerated examples)
- Penetration enhancer present: polyol/ester/ether/sulfoxide/fatty acid/fatty ester class at 0.001-15%
- Droplets form on application; non-foaming
- Substantially propellant-free
- Substantially propylene-glycol-free
- Viscosity within 10-15,000 cP if claim 24 is asserted
Claim 15 protected formulation class (betamethasone-focused)
Protected for betamethasone compound topical spray with sorbitan stearate emulsifier and the same non-occlusivity, water, and water-immiscible substance features, plus optional polymer/penetration enhancer/non-foaming/droplet/propellant/propyleneglycol and betamethasone concentration range.
How strong is the patent estate for non-occlusive sprayable steroid topicals?
Given only the claim text, the strength profile can be evaluated at the claim-architecture level:
- Broad independent anchors: sprayable + sorbitan stearate + non-occlusive + steroid + emulsion components
- Multiple dependent narrowing hooks: polymer family, penetration enhancer range, viscosity, droplet formation, foam control, and ingredient exclusions
- Two independent claims: claim 1 (any steroid genus limited by dependent list) and claim 15 (betamethasone compound)
In litigation, this structure typically supports:
- asserting claim 1/15 for broad composition coverage and
- asserting dependent claims where an accused product includes polymers, penetration enhancers, or where formulation attributes (non-foaming, viscosity) are measurable.
However, the non-occlusive performance limitation can be a factual battleground, and “sprayable” is also often contested.
What competitor products face the highest US 9,439,911 risk?
Without the Orange Book entry set or prosecution history, risk can still be stratified from the claim-required ingredients:
Highest-risk design space
Products likely at the center of claim scope if they are:
- sprayable topical corticosteroid formulations
- made as an emulsion with sorbitan stearate as a non-polymeric emulsifier
- formulated to be non-occlusive (reduced residue/occlusion)
- and avoid propellant and propylene glycol
Lower-risk (likely easier design-around) characteristics
- Products that use different emulsifiers (no sorbitan stearate-containing non-polymeric emulsifier)
- Products that are not sprayable (different dosage form/delivery)
- Products that include propylene glycol and do not qualify as “substantially free”
- Products that use occlusive bases inconsistent with the non-occlusive requirement
What generic entry risks exist for US 9,439,911?
The claims are directed to a formulation and use for multiple steroid-responsive dermatoses. Generic entry risk is driven by whether a generic applicant seeks to market a sprayable non-occlusive sorbitan stearate emulsified steroid.
Practical generic risk scenario
- If a generic sponsor can match active ingredient(s) and avoid sorbitan stearate (or avoid non-occlusive behavior) it can reduce infringement.
- If it uses sorbitan stearate emulsification and similar vehicle system to meet spray performance and consumer sensorial targets, it can preserve infringement exposure even if the steroid salt/ester form differs, unless it also avoids the claim’s non-occlusive criterion and excluded ingredients.
What patent landscape questions can be answered from claim text alone?
Key unanswered items from the record provided (and therefore not restated here as facts) include:
- the patent term end date in the US,
- continuation/divisional relationships,
- related families,
- whether there are multiple asserted patents in the same litigation/infringement campaign,
- and the FDA/NDA or ANDA linkage for this specific patent.
Accordingly, this analysis focuses strictly on claim scope mechanics and the infringement/avoidance vectors embedded in claims 1–30.
Claim-by-claim scope matrix (infringement-critical limitations)
| Claim |
Key additional limitations beyond claim 1/15 |
Scope impact for an accused product |
| 1 |
Steroid + sorbitan stearate non-polymeric emulsifier + water + water-immiscible + substantially non-occlusive + sprayable |
Broadest independent composition coverage; infringement turns on sorbitan stearate, non-occlusivity, and sprayability |
| 2 |
Enumerated steroid list |
Narrows steroid identity when asserted with claim 2 |
| 3 |
Polymer added |
Creates second-tier infringement if polymer present |
| 4 |
Polymer families: cellulose/gum/alginate/phthalate |
Narrows polymer selection |
| 5 |
Specific polymer exemplars |
Tightens dependency; easier to assess |
| 6 |
Water-immiscible substance list |
Broad list makes this element hard to escape |
| 7 |
Penetration enhancer added |
Another second-tier hook |
| 8 |
Penetration enhancer 0.001% to 15% w/w |
Numeric range can be decisive |
| 9 |
Penetration enhancer class list |
Determines enhancer eligibility |
| 10 |
Specific betamethasone + specific polymer subset |
Limits to betamethasone species and cellulose-type exemplars |
| 11 |
Forms droplets upon application |
Helps enforce “spray” sensory/behavior limitation |
| 12 |
Substantially non-foaming |
Another measurable property |
| 13 |
Substantially free of propellant |
Constrains formulation/dispensing system |
| 14 |
Substantially free of propylene glycol |
Vehicle exclusion useful in design-around |
| 15 |
Betamethasone compound instead of general steroid |
Independent coverage for betamethasone products |
| 16 |
Betamethasone concentration equivalent 0.025%–0.1% base |
Numeric limitation for betamethasone products |
| 17 |
Betamethasone compound species list |
Salt/ester identity limitation |
| 18 |
Polymer added |
Secondary narrowing |
| 19 |
Polymer exemplars list |
Diagnostic dependency |
| 20 |
Water-immiscible substance list |
Broad |
| 21 |
Penetration enhancer added |
Secondary narrowing |
| 22 |
Penetration enhancer 0.001%–15% |
Numeric |
| 23 |
Specific betamethasone dipropionate + polymer subset |
Narrow subgroup |
| 24 |
Viscosity 10–15,000 cP |
Process/vehicle constraint |
| 25 |
Forms droplets |
Spray characteristic |
| 26 |
Substantially non-foaming |
Foam constraint |
| 27 |
Substantially free of propellant |
Delivery constraint |
| 28 |
Substantially free of propylene glycol |
Vehicle constraint |
| 29 |
Method for listed skin conditions using claim 1 composition |
Method-of-use coverage for broad steroid indications within the listed conditions |
| 30 |
Same method but using claim 15 composition |
Method-of-use hook for betamethasone compositions |
How does US 9,439,911 compare with typical topical steroid IP?
In the US topical steroid space, many formulation patents cluster around one or more of:
- vehicle rheology and sprayability,
- penetration enhancement and skin deposition,
- occlusion control and residue management,
- avoidance of specific excipients linked to tolerability.
US 9,439,911 is distinctive in that it hard-codes:
- sorbitan stearate as part of the non-polymeric emulsifier, and
- “substantially non-occlusive” as a formulation-performance limitation, while also tying the product to spray behavior and non-foaming.
That combination increases both coverage and proof complexity: it narrows the field by requiring a specific emulsifier class and non-occlusive performance, while also providing multiple dependent pathways for enforcement.
Key Takeaways
- US 9,439,911 claims a sprayable topical steroid emulsion with a non-polymeric sorbitan stearate emulsifier, water, water-immiscible phase, and substantially non-occlusive skin performance.
- The independent claims are anchored to formulation composition (claims 1 and 15) and are backed by multiple dependent claim “switches” tied to polymer class, penetration enhancer class and % range, droplet formation, non-foaming, propellant-free, propylene-glycol-free, and viscosity.
- Betamethasone products face elevated risk because claim 15 adds a dedicated independent betamethasone pathway and a betamethasone concentration/salt dependency (claims 16–17).
- Freedom-to-operate for generic or follow-on sprays hinges on avoiding at least one of the hard anchors: sorbitan stearate in a non-polymeric emulsifier, substantially non-occlusive behavior, or sprayability, plus potentially avoiding propellant and propylene glycol if the asserted dependent claims are targeted.
FAQs
- What does “substantially non-occlusive to the skin” mean for infringement analysis of US 9,439,911?
- Which design-around changes matter most: switching sorbitan stearate emulsifiers, changing steroid identity, or altering spray delivery characteristics?
- How do the penetration enhancer limits (0.001%–15% by weight) interact with generic formulation reformulation for topical sprays?
- If a product is propellant-free but contains propylene glycol, does it still avoid claims 14/28?
- Do the method-of-use claims (29–30) increase enforcement risk against ANDA filers, or are they mainly relevant for settlements and label-based agreements?
References
- US Patent 9,439,911.
More… ↓
⤷ Start Trial
|
